Trinity Biotech Expands Global Rollout Of Next-Generation HbA1c Column System

Company advances its mission to deliver next-generation diabetes management solutions and expand global market penetration

Next-generation column technology enhances efficiency, expands recurring revenue potential, and strengthens Trinity Biotech's competitive position in the $2B+ HbA1c market

DUBLIN, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has secured regulatory clearances in multiple countries,  enabling the expanded rollout of its next-generation high-capacity HbA1c column system for the Premier Hb9210 analyzer which is now available in more than 10 countries, including the United States. The upgraded system significantly increases testing throughput, improves operational efficiency, and supports greater recurring revenue opportunities and margin expansion as the company strengthens its leadership position in the growing global HbA1c market.

The global laboratory HbA1c market is estimated to be currently worth over $2 billion annually and is expected to grow to exceed $3.5 billion by 2030.  This expected rise in the HbA1c market is primarily driven by the increasing prevalence of diabetes1.

Designed for Trinity Biotech's Premier Hb9210 analyzer, the company's dedicated laboratory HbA1c solution, the upgraded column system delivers up to four times the testing capacity compared to the existing column system and minimizes instrument downtime through improved stability and reduced maintenance requirements. These operational gains create a more efficient workflow for clinical laboratories and support broader adoption of the platform.

Key Highlights:

• Reduced downtime and improved operational efficiency, enabling higher throughput.
• Increased column stability, minimizing maintenance interruptions and reducing operator workload.
• The latest software update delivers additional automation of routine tasks enabling greater productivity and cost savings.

Trinity Biotech's Premier Hb9210 solution continues to be recognized as a gold standard in HbA1c testing, with published peer-reviewed scientific comparative studies continuing to confirm the strong clinical performance of the company's HbA1c analyzer system2.  In addition, a recent article published by the Association for Diagnostics and Laboratory Medicine states "Still, BAC (Trinity Biotech) remains the method with the highest specificity for HbA1c currently on the market."3